4.5 Article

The levels of water-soluble and triton-soluble Aβ are increased in Alzheimer's disease brain

Journal

BRAIN RESEARCH
Volume 1450, Issue -, Pages 138-147

Publisher

ELSEVIER
DOI: 10.1016/j.brainres.2012.02.041

Keywords

Alzheimer's disease; Amyloid beta-protein; Water-soluble A beta; SDS-stable A beta dimer; Neuritic plaque

Categories

Funding

  1. Cure Alzheimer's Fund
  2. Tau Consortium
  3. Astra Zeneca
  4. Pfizer
  5. Eli Lilly
  6. C2N Diagnostics
  7. NIH [IRO1AGO27443, P50 AG05681, P01 AG03991]
  8. NIH Neuroscience Blueprint Interdisciplinary Center [P30 NS057105]
  9. Charles F. & Joanne Knight Alzheimer's Disease Research Centre
  10. Science foundation Ireland [08/1N.1/B2033]

Ask authors/readers for more resources

Although plaques composed of the amyloid beta-protein (A beta) are considered a defining feature of Alzheimer's disease (AD), they are also found in cognitively normal individuals and extensive evidence suggests that non-plaque, water-soluble forms of A beta may play a role in AD pathogenesis. However, the relationship between the levels of water-soluble A beta and the clinical severity of disease has never been investigated. Here, we present results of a pilot study designed to examine the levels of water-soluble forms of A beta in brains of individuals who died at clinically distinct stages of AD. Using a serial extraction method, we also investigated the levels of triton-soluble and formic acid-soluble A beta. We found that water-soluble and detergent-soluble A beta monomer and SDS-stable dimer were elevated in AD and that the levels of water soluble A beta did not increase with plaque pathology. These results support the notion that both water- and detergent-soluble A beta are important in AD and are not simply released from plaques by mechanical disruption. Moreover, the fact that the levels of water- and triton-soluble A beta were similar in very mild/mild AD and moderate/severe AD suggests that once a certain level of these species is attained, further accumulation is not necessary for the disease to progress. Consequently, therapeutic targeting of water-soluble A beta should best benefit individuals in earliest phases of the disease process. (C) 2012 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available